Eli Lilly and Immunocore to test combination therapy

Eli Lilly and Company and Immunocore Ltd have agreed to test two potential combination therapies for the treatment of melanoma that involve Immunocore’s T cell receptor technology together with two of Lilly’s experimental kinase inhibitors.